1. The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas
- Author
-
Robert W. Allan and Ian M. Bovio
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,CD30 ,Adolescent ,CD33 ,Sialic Acid Binding Ig-like Lectin 3 ,Antigens, Differentiation, Myelomonocytic ,Biology ,CD13 Antigens ,Immunophenotyping ,Antigens, CD ,hemic and lymphatic diseases ,medicine ,Biomarkers, Tumor ,Anaplastic lymphoma kinase ,Humans ,Anaplastic Lymphoma Kinase ,Child ,Anaplastic large-cell lymphoma ,Aged ,Retrospective Studies ,Aged, 80 and over ,Large-cell lymphoma ,Infant ,Receptor Protein-Tyrosine Kinases ,General Medicine ,Middle Aged ,Protein-Tyrosine Kinases ,medicine.disease ,Flow Cytometry ,Molecular biology ,Immunohistochemistry ,Lymphoma ,Child, Preschool ,Lymphoma, Large-Cell, Anaplastic ,Female ,CD5 - Abstract
We retrospectively studied the immunophenotype by flow cytometry of 20 anaplastic large cell lymphomas (ALCLs) (9 anaplastic lymphoma kinase [ALK]+ and 11 ALK-) with a particular emphasis on the aberrant expression of the myeloid associated antigens CD13 and/or CD33. All ALCLs expressed CD45, HLA-DR, and CD30. Most (8/9) ALK+ ALCLs expressed at least 1 surface T-cell antigen (CD4, 6/9 [67%]; CD7, 6/9 [67%]; CD2, 5/9 [56%]; CD5, 2/9 [22%]; CD8, 2/9 [22%]; CD3, 1/9 [11%]). All ALK-ALCLs expressed at least 1 surface T-cell antigen (CD3, 7/11 [64%]; CD4, 6/11 [55%]; CD2, 6/11 [55%]; CD7, 2/11 [18%]; CD5, 1/11 [9%]; CD8, 1/11 [9%]). CD13 and/or CD33 were expressed in all (9/9) ALK+ ALCLs compared with 1 of 11 ALK-ALCLs (9%) (P < .0001). Surface CD3 was more likely expressed in ALK-ALCLs (7/11) compared with ALK+ ALCLs (1/9) (P .03). The myeloid-associated antigens CD13 and/or CD33 are sensitive but not entirely specific markers of ALK+ ALCLs and should not be misinterpreted as indicating myeloid sarcoma.
- Published
- 2008